...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: So i made a couple of calls

and the gist of those conversations is that they have a 4 month target for an all in done deal on Zenith at US$20 a share and a well known big pharmco is the favorite suitor at the moment and Pfizer can go stick a pineapple up theirs for not bargaining seriousy. Oh yes, there wull be a fund raising in the near future at an impressively optimistic price, especially considering the price of the shares  in the pink, gray or whatever market. The story is consistent and the storytellers are sincere but i still think this may all a DM con to string the retail shareholders along with faint hope and keep those enormous and, in my opinion, undeserved paycheques coming in. To reiterate, i do not believe that any of this will come to pass. Wll Lucy ever not pull the football away at the last moment when Charloe Brown goes to kick it?

As someone important once said, DM is the best promoter i ever met and he cost me a lot of money (talking about RVX and the huge runup where he did not sell).

As for RVX, no one has anything to say about what is going on which is funny considering that the big update is January 28?

Share
New Message
Please login to post a reply